.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EB24_Mavacamten.Mavacamten

Information

Mavacamten is a selective, allosteric inhibitor of cardiac myosin ATPase, developed primarily for the treatment of hypertrophic cardiomyopathy (HCM). It works by decreasing excessive contractility and improving cardiac relaxation. Mavacamten (marketed as Camzyos) is approved for use in adults with symptomatic obstructive HCM.

Pharmacokinetics

Pharmacokinetic parameters are reported in healthy volunteers and patients with HCM after single and multiple oral doses.

References

1. Wu, X, et al., & Zhang, J (2024). Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes. Clinical and translational science 17(7) e13877–None. DOI:10.1111/cts.13877 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39014868

2. Tian, Z, et al., & Han, Y (2023). Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy. BMJ open 13(6) e071473–None. DOI:10.1136/bmjopen-2022-071473 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37336533

3. Chiang, M, et al., & Gaohua, L (2023). Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype. Clinical pharmacology and therapeutics 114(4) 922–932. DOI:10.1002/cpt.3005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37467157

Revisions

• 06/2025 initial generated model